230 related articles for article (PubMed ID: 17976015)
1. Defining the extended substrate specificity of kallikrein 1-related peptidases.
Borgoño CA; Gavigan JA; Alves J; Bowles B; Harris JL; Sotiropoulou G; Diamandis EP
Biol Chem; 2007 Nov; 388(11):1215-25. PubMed ID: 17976015
[TBL] [Abstract][Full Text] [Related]
2. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U
Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340
[TBL] [Abstract][Full Text] [Related]
4. Interdependence of kallikrein-related peptidases in proteolytic networks.
Beaufort N; Plaza K; Utzschneider D; Schwarz A; Burkhart JM; Creutzburg S; Debela M; Schmitt M; Ries C; Magdolen V
Biol Chem; 2010 May; 391(5):581-7. PubMed ID: 20302517
[TBL] [Abstract][Full Text] [Related]
5. The canine kallikrein-related peptidase 14: structural characterization, alternative splicing and differential expression in mammary cancer.
Angelopoulou K; Prassas I; Yousef GM
Gene; 2009 Oct; 446(2):68-74. PubMed ID: 19619623
[TBL] [Abstract][Full Text] [Related]
6. Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14.
de Veer SJ; Swedberg JE; Parker EA; Harris JM
Biol Chem; 2012 Apr; 393(5):331-41. PubMed ID: 22505516
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin.
Backes BJ; Harris JL; Leonetti F; Craik CS; Ellman JA
Nat Biotechnol; 2000 Feb; 18(2):187-93. PubMed ID: 10657126
[TBL] [Abstract][Full Text] [Related]
8. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology.
Shaw JL; Diamandis EP
Biol Chem; 2008 Jun; 389(6):681-8. PubMed ID: 18627298
[TBL] [Abstract][Full Text] [Related]
9. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.
Mukai S; Fukushima T; Naka D; Tanaka H; Osada Y; Kataoka H
FEBS J; 2008 Mar; 275(5):1003-17. PubMed ID: 18221492
[TBL] [Abstract][Full Text] [Related]
10. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.
Debela M; Beaufort N; Magdolen V; Schechter NM; Craik CS; Schmitt M; Bode W; Goettig P
Biol Chem; 2008 Jun; 389(6):623-32. PubMed ID: 18627343
[TBL] [Abstract][Full Text] [Related]
11. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies.
Yousef GM; Magklara A; Chang A; Jung K; Katsaros D; Diamandis EP
Cancer Res; 2001 Apr; 61(8):3425-31. PubMed ID: 11309303
[TBL] [Abstract][Full Text] [Related]
12. Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense.
Shaw JL; Petraki C; Watson C; Bocking A; Diamandis EP
Biol Chem; 2008 Dec; 389(12):1513-22. PubMed ID: 18844451
[TBL] [Abstract][Full Text] [Related]
13. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy.
Komatsu N; Saijoh K; Kuk C; Shirasaki F; Takehara K; Diamandis EP
Br J Dermatol; 2007 May; 156(5):875-83. PubMed ID: 17459012
[TBL] [Abstract][Full Text] [Related]
14. Targeting the kallikrein-related peptidases for drug development.
Sotiropoulou G; Pampalakis G
Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
[TBL] [Abstract][Full Text] [Related]
15. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides.
Béliveau F; Désilets A; Leduc R
FEBS J; 2009 Apr; 276(8):2213-26. PubMed ID: 19302215
[TBL] [Abstract][Full Text] [Related]
16. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein.
Komatsu N; Saijoh K; Otsuki N; Kishi T; Micheal IP; Obiezu CV; Borgono CA; Takehara K; Jayakumar A; Wu HK; Clayman GL; Diamandis EP
Clin Chim Acta; 2007 Feb; 377(1-2):228-36. PubMed ID: 17140555
[TBL] [Abstract][Full Text] [Related]
18. S(1)' and S(2)' subsite specificities of human plasma kallikrein and tissue kallikrein 1 for the hydrolysis of peptides derived from the bradykinin domain of human kininogen.
Lima AR; Alves FM; Angelo PF; Andrade D; Blaber SI; Blaber M; Juliano L; Juliano MA
Biol Chem; 2008 Dec; 389(12):1487-94. PubMed ID: 18844446
[TBL] [Abstract][Full Text] [Related]
19. Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases.
Dong Y; Harrington BS; Adams MN; Wortmann A; Stephenson SA; Lisle J; Herington A; Hooper JD; Clements JA
Biol Chem; 2014 Sep; 395(9):977-90. PubMed ID: 24854540
[TBL] [Abstract][Full Text] [Related]
20. Putative kallikrein substrates and their (patho)biological functions.
Yu Y; Prassas I; Diamandis EP
Biol Chem; 2014 Sep; 395(9):931-43. PubMed ID: 24854536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
